Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 218

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 218
---
    7,205

    25,429

    —

    Total operating expenses

    341,506

    397,311

    385,494

    Loss from operations

    (162,549
    )

    (227,035
    )

    (200,186
    )

    Interest and other income, net

    14,534

    15,531

    4,056

    Interest expense

    (11,580
    )

    (13,800
    )

    (4,238
    )

    Net loss

    (159,595
    )

    (225,304
    )

    (200,368
    )

    Add: Net loss attributable to noncontrolling interest

    103

    54

    177

    Net loss attributable to Adaptive Biotechnologies Corporation
     
    $
    (159,492
    )
     
    $
    (225,250
    )
     
    $
    (200,191
    )

    Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted
     
    $
    (1.08
    )
     
    $
    (1.56
    )
     
    $
    (1.40
    )

    Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

    147,101,648

    144,383,294

    142,515,917

    Other Financial and Operating Data:

    Adjusted EBITDA(1)
     
    $
    (80,371
    )
     
    $
    (116,413
    )
     
    $
    (121,589
    )

(1) Adjusted EBITDA is a non-GAAP financial measure that we define as net loss attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, impairment costs for long-lived assets, restructuring expense and share-based compensation expense. See “Adjusted EBITDA” below for a reconciliation between Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, and a discussion about the limitations of Adjusted EBITDA.

Comparison of the Years Ended December 31, 2024 and 2023

Revenue